Off-label use of bevacizumab for the treatment of age-related macular degeneration: What is the evidence?

Drugs and Aging

Volumn 26, Issue 4, 2009, Pages 295-320

  Ziemssen, Focke ^a   Grisanti, Salvatore ^b   Bartz Schmidt, Karl Ulrich ^a   Spitzer, Martin S ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

BINDING AFFINITY; BLEEDING; BREAST CANCER; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENDOPHTHALMITIS; GERIATRIC CARE; GLAUCOMA; HUMAN; IC 50; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; NONHUMAN; OFF LABEL DRUG USE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; AGE; COMPARATIVE STUDY; DRUG LABELING; ECONOMICS; RETINA MACULA DEGENERATION;

AGE FACTORS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG LABELING; HUMANS; MACULAR DEGENERATION;

EID: 67649996349     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-200926040-00002     Document Type: Review

References (181)

1. Cohen DJ, Hochster HS. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 2007; 7 Suppl. 1: S21-7
2. Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008; 8 (5): 689-99
3. Spalding BJ. Thumbs up for Avastin. Nat Biotechnol 2008; 26 (4): 365
4. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005; 69 Suppl. 3: 46-56
5. Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov 2004; 3 (12): 995-6
6. Charatan F. News feature: costly US. Anticancer drugs pose problems for doctors and patients. BMJ 2008; 337: a778
7. Ziemssen F, Heiduschka P, Schraermeyer U. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2007; 27 (8): 1154-6
8. Waisbourd M, Loewenstein A, Goldstein M, et al. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007; 24 (8): 643-62
9. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112 (6): 1035-47
10. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36 (4): 331-5
11. Ziemssen F, Bartz-Schmidt KU, Grisanti S. (Side) effects of VEGF inhibition. Ophthalmologe 2006; 103 (6): 484-92
12. Ziemssen F, Heiduschka P, Peters S, et al. Chances and risks of anti-VEGF therapy. Klin Monatsbl Augenheilkd 2008; 225 (9): 770-8
13. Smit DP, Meyer D. Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol 2007; 1 (3): 273-84
14. Avastin information. Genentech, Inc., 2008 [online]. Available from URL: http://www.gene.com/gene/products/ information/oncology/avastin [Accessed 2009 Feb 27]
15. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-a in patients with choroidal neovascularization. Ophthalmology 2008; 115 (10): 1750-5
16. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114 (12): 2179-82
17. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7 (4): 335-45
18. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmaco-kinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27 (5): 536-44
19. Dib E, Maia M, Longo-Maugeri IM, et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci 2008; 49 (3): 1097-100
20. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48 (6): 2814-23
21. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26 (3): 262-9
22. Kaempf S, Johnen S, Salz AK, et al. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 2008; 49 (7): 3164-71
23. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin): a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333 (2): 328-35
24. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293 (4): 865-81
25. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007; 245 (12): 1837-42
26. Klettner AK, Roider J. Comparison of bevacizumab, ranibizumab and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008; 49 (10): 4523-7
27. Olsen TW. Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 2007; 144 (2): 281-3
28. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina 2007; 27 (9): 1196-200
29. Hayden EC. Battle over eye medicine gives drugmaker a dose of reality. Nat Med 2008; 14 (2): 108
30. Mones J. Bevacizumab or ranibizumab, or the tale of Robin Hood and King Richard Lion Heart. Arch Soc Esp Oftalmol 2007; 82 (9): 529-30
31. Menendez de Lucas JA, Morcillo LR. The responsibility of the ophthalmologist when using drugs which are uneconomic from the perspective of the pharmaceutical industry. Arch Soc Esp Oftalmol 2007; 82 (5): 257-9
32. Rosenfeld PJ. Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 2006; 142 (1): 141-3
33. la Cour M. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis? Acta Ophthalmol Scand 2007; 85 (1): 2-4
34. Raftery J, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007; 91 (9): 1244-6
35. Raftery JP, Lotery A. The cheaper drug, bevacizumab, should be referred to NICE. BMJ 2007; 334 (7590): 381-2
36. Neubauer AS, Holz FG, Schrader W, et al. Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration. Klin Monatsbl Augenheilkd 2007; 224 (9): 727-32
37. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473-81
38. Brown MM, Brown GC, Brown HC, et al. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115 (6): 1039-45
39. Wong D, Kyle G. Some ethical considerations for the 'offlabel' use of drugs such as Avastin. Br J Ophthalmol 2006; 90 (10): 1218-9
40. Klein RM, Klein RB. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration. Retina 2007; 27 (9): 1163-5
41. Michels S. Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 2006; 90 (11): 1333-4
42. Chong NV, Adewoyin T. Intravitreal injection: balancing the risks. Eye 2007; 21 (3): 313-6
43. Kumar N, Sebastian R, Harding S, et al. Bevacizumab: a word of caution. Can J Ophthalmol 2007; 42 (5): 760-1
44. Canning C, Lotery A. Bevacizumab: a new way of doing business? Eye 2006; 20 (9): 985-7
45. Ziemssen F, Grisanti S, Bartz-Schmidt KU. The International Intravitreal Bevacizumab Safety Survey. Br J Ophthalmol 2006; 90 (11): 1440-1
46. Kimmelman J. Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration. Retina 2007; 27 (9): 1166-7
47. Gillies MC. What we don't know about Avastin might hurt us. Arch Ophthalmol 2006; 124 (10): 1478-9
48. la Cour M, Kiilgaard JF, Nissen MH. Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging 2002; 19 (2): 101-33
49. Azad R, Chandra P, Gupta R. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007; 55 (6): 441-3
50. Buys YM. Bevacizumab: the need for controlled studies to move forward. Can J Ophthalmol 2007; 42 (6): 789
51. Patel PJ, Chen FK, Ikeji F, et al. Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49 (3): 1084-8
52. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007; 85 (5): 563-5
53. Algvere PV, Steen B, Seregard S, et al. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2007; 86 (5): 482-9
54. Brantley Jr MA. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114 (12): 2168-73
55. Heimes B, Lommatzsch A, Zeimer M, et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 2008; 246 (9): 1229-34
56. Krebs I, Ansari-Shahrezaei S, Goll A, et al. Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluor-escein angiography. Graefes Arch Clin Exp Ophthalmol 2008; 246 (6): 811-5
57. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. The GRADE Working Group. BMC Health Serv Res 2004; 4 (1): 38
58. Oxford Centre for Evidence-Based Medicine. Levels of evidence and grade of recommendation. CEBM [online]. Available from URL: http://www.cebm.net/index. aspx? o=1025 2001 [Accessed 2009 Feb 27]
59. Avery RL, Pieramici DJ, Rabena MD, et al. Intraitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113 (3): 363-72
60. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26 (4): 383-90
61. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26 (5): 495-511
62. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142 (1): 1-9
63. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006; 47 (10): 4569-78
64. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 2007; 245 (5): 651-5
65. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245 (1): 68-73
66. Lazic R, Gabric N, Dekaris I, et al. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol 2007; 31 Suppl. 1: 77-81
67. Aggio FB, Farah ME, Silva WC, et al. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007; 245 (2): 215-20
68. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26 (9): 994-8
69. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245 (7): 941-8
70. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143 (3): 510-2
71. Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007; 17 (2): 230-7
72. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007; 27 (4): 432-8
73. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27 (4): 439-44
74. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007; 27 (4): 445-50
75. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 2007; 27 (4): 451-7
76. Joeres S, Heussen FM, Treziak T, et al. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007; 245 (11): 1597-602
77. Pedersen R, Soliman W, Lund-Andersen H, et al. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007; 85 (5): 526-33
78. Lux A, Llacer H, Heussen FM, et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007; 91 (10): 1318-22
79. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114 (6): 1179-85
80. Lazic R, Gabric N, Dekaris I, et al. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. Coll Antropol 2007; 31 Suppl. 1: 71-5
81. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92 (1): 70-3
82. Falkenstein IA, Cheng L, Morrison VL, et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007; 27 (6): 701-6
83. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2008; 22 (1): 82-6
84. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007; 144 (6): 886-92
85. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125 (10): 1357-61
86. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 2008; 92 (2): 210-2
87. Madhusudhana KC, Hannan SR, Williams CP, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007; 91 (12): 1716-7
88. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145 (2): 249-56
89. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92 (3): 356-60
90. Azad RV, Khan MA, Chanana B, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 2008; 52 (1): 52-6
91. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008; 146 (1): 91-5
92. Ghazi NG, Knape RM, Kirk TQ, et al. Intravitreal bevacizumab (Avastin) treatment of retinal angiomatous proliferation. Retina 2008; 28 (5): 689-5
93. Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (Avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol. Epub 2008 Jun 11
94. Falkenstein IA, Cochran DE Azen SP, et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and Early Treatment Diabetic Retinopathy Study charts. Ophthalmology 2008; 115 (2): 319-23
95. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. BrJOphthalmol 2006;90(10): 1316-21
96. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006; 26 (5): 512-8
97. Bakri SJ, Cameron JD, McCannel CA, et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006; 142 (1): 162-4
98. Feiner L, Barr EE, Shui YB, et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006; 26 (8): 882-8
99. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26 (3): 257-61
100. Inan UU, Avci B, Kusbeci T, et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007; 48 (4): 1773-81
101. Kim JH, Kim C, Kim JH, et al. Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology 2008; 29 (6): 1131-5
102. Heiduschka P, Julien S, Hofmeister S, et al. Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 2008; 28 (1): 46-55
103. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005; 14 (5): 207-21
104. Iriyama A, Chen YN, Tamaki Y, et al. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007; 91 (9): 1230-3
105. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90 (9): 1178-82
106. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO: a multifocal-ERG and OCT study. Doc Ophthalmol 2008; 116 (2): 147-52
107. Karanjia R, Eng KT, Gale J, et al. Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration (ARMD). Br J Ophthalmol 2008; 92 (9): 1248-52
108. Ziemssen F, Luke M, Messias A, et al. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2008; 28 (2): 101-9
109. Shetty R, Pai SA, Vincent A, et al. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 2008; 116 (2): 129-35
110. Stahl A, Feltgen N, Fuchs A, et al. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Doc Ophthalmol 2009 Apr; 118 (2): 81-8
111. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143 (6): 995-1002
112. Bakri SJ, Snyder MR, Pulido JS, et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006; 26 (5): 519-22
113. Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91 (6): 827-31
114. Aggio FB, Farah ME, de Melo GB, et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 2007; 21 (3): 408-9
115. Kopel AC, Carvounis PE, Holz ER. Bacillus cereus endophthalmitis following intravitreous bevacizumab injection. Ophthalmic Surg Lasers Imaging 2008; 39 (2): 153-4
116. Alkuraya HS, Al-Kharashi AS, Alharthi E, et al. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol. Epub 2008 Jun 5
117. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246 (5): 779-81
118. Pieramici DJ, Avery RL, Castellarin AA, et al. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006; 26 (7): 841-2
119. Hasler S, Schmid MK, Becht CN. Acute anterior non-granulomatous uveitis after intravitreal injection of bevacizumab. Klin Monatsbl Augenheilkd 2008; 225 (5): 446-7
120. Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008; 24 (3): 362-3
121. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23 (3): 240-2
122. Neri P, Mariotti C, Mercanti L, et al. Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin®). Int Ophthalmol 2008; 28 (6): 425-7
123. Amselem L, Diaz-Llopis M, Garcia-Delpech S, et al. Papulopustular eruption after intravitreal bevacizumab (Avastin®). Acta Ophthalmol 2009; 87 (1): 110-1
124. Ziemssen F, Warga M, Neuhann IM, et al. Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? [letter]. Br J Ophthalmol 2006; 90 (7): 922
125. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008; 22 (4): 590-1
126. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145 (5): 879-82
127. Mason III JO, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28 (4): 564-7
128. Ziemssen F, Dietz K, Bartz-Schmidt KU. Postoperative antibiotics after intravitreal injection? Ophthalmologe 2008; 105 (2): 180-1
129. de Caro JJ, Ta CN, Ho HK, et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 2008; 28 (6): 877-83
130. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 2009; 23 (1): 181-5
131. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42 (6): 807-11
132. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007; 27 (8): 1044-7
133. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication [letter]. Eye 2007; 21 (12): 1541
134. Meyer CH, Mennel S, Horle S, et al. Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 2007; 143 (1): 169-70
135. Chieh JJ, Fekrat S. Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. Ann Ophthalmol (Skokie) 2007; 39 (1): 51-2
136. Charles S, Rosenfeld PJ, Gayer S. Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections. Retina 2007; 27 (7): 813-5
137. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90 (11): 1344-9
138. Meyer CH, Mennel S, Schmidt JC, et al. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006; 90 (9): 1207-8
139. Gelisken F, Ziemssen F, Voelker M, et al. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol Scand 2006; 84 (6): 833-4
140. Nicolo M, Ghiglione D, Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalmol 2006; 16 (5): 770-3
141. Spandau UH, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 2006; 142 (6): 1068-70
142. Shah CP, Hsu J, Garg SJ, et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 2006; 142 (6): 1070-72
143. Bakri SJ, Patel SP. Retinal pigment epithelial tear following intravitreal bevacizumab. Eye 2007; 21 (3): 424-5
144. Gamulescu MA, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2007; 245 (7): 1037-40
145. Mathews JP, Jalil A, Lavin MJ, et al. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin): optical coherence tomography and fluorescein angiographic findings. Eye 2007; 21 (7): 1004-5
146. Hannan SR, Madhusudhana KC, Lotery AJ, et al. Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration. Br J Ophthalmol 2007; 91 (7): 977-8
147. Subramanyam A, Phatak S, Chudgar D. Large retinal pigment epithelium rip following serial intravitreal injection of Avastin in a large fibrovascular pigment epithelial detachment. Indian J Ophthalmol 2007; 55 (6): 483-6
148. Kawashima M, Mori R, Mizutani Y, et al. Choroidal folds and retinal pigment epithelium tear following intravitreal bevacizumab injection for exudative age-related macular degeneration. Jpn J Ophthalmol 2008; 52 (2): 142-4
149. Forooghian F, Cukras C, Chew EY. Retinal angiomatous proliferation complicated by pigment epithelial tear following intravitreal bevacizumab treatment. Can J Ophthalmol 2008; 43 (2): 246-8
150. Mennel S, Callizo J, Schmidt JC, et al. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 2007; 85 (6): 689-91
151. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2007; 27 (5): 535-40
152. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27 (5): 541-51
153. Shaikh S, Olson JC, Richmond PP. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Indian J Ophthalmol 2007; 55 (6): 470-2
154. Garg S, Brod R, Kim D, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 2008; 36 (3): 252-6
155. Weinberger AW, Thiel M, Mohammadi B, et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 2007; 144 (2): 294-6
156. Arias L, Caminal JM, Rubio M, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. Eur J Ophthalmol 2007; 17 (6): 992-5
157. Gelisken F, Ziemssen F, Voelker M, et al. Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration [letter]. Eye 2008
158. Chiang A, Chang LK, Yu F, et al. Predictors of anti-VEGF associated retinal pigment epithelial tear using FA and OCT analysis. Retina. Epub 2008 Jul 14
159. Leitritz M, Gelisken F, Inhoffen W, et al. Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study. Eye 2008; 22 (12): 1504-7
160. Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008; 92 (4): 509-12
161. Dafer RM, Schneck M, Friberg TR, et al. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007; 22 (3): 201-4
162. Liew G, Mitchell P, Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007; 356 (7): 747-8
163. Csaky KG, Gordiyenko N, Rabena MG, et al. Pharmacokinetics of intravitreal bevacizumab in humans [abstract]. Invest Ophthal Vis Sci 2007; 48: A4936
164. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146 (4): 508-12
165. Hetland ML, Christensen IJ, Lottenburger T, et al. Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers 2008; 24 (1): 1-10
166. Ziemssen F, Zhu Q, Peters S, et al. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol. Epub 2008 Apr 17
167. Rodrigues EB, Shiroma H, Meyer CH, et al. Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007; 85 (8): 915-6
168. Byeon SH, Kwon OW, Lee SC. Transient global amnesia following intravitreal injection of bevacizumab. Acta Ophthalmol. Epub 2008 Jun 5
169. Park HJ, Guy J. Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication? [letter]. Binocul Vis Strabismus Q 2007; 22 (4): 209
170. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113 (10): 1695-15
171. Scartozzi R, Chao JR, Walsh AC, et al. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye. Epub 2008 Jun 6
172. Pande A, Lombardo J, Spangenthal E, et al. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 2007; 27 (5B): 3465-70
173. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007; 85 (1): 119-20
174. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62 (5): 779-86
175. McGimpsey SJ, Gillies MC. Treatment of macular degeneration: controversy and hope. Br J Ophthalmol 2008; 92 (3): 436-7
176. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246 (1): 81-7
177. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008; 86 (4): 372-76
178. National Eye Institute (NEI). Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial [ClinicalTrials.gov identifier NCT00593450]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 5]
179. Klinikum Bremen-Mitte, gGmbH. Prevention of vision loss in patients with age-related macular degeneration (AMD) by intravitreal injection of bevacizumab and ranibizumab [ClinicalTrials.gov identifier NCT00559715]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 24]
180. The intravitreal use of bevacizumab (Avastin) in age-related macular degeneration (IVAN) [online]. Available from URL: http://www.ivan-trial.co.uk/ [Accessed 2009 Feb 27]
181. The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery. Manta study: Avastin versus Lucentis in age related macular degeneration (MANTA) [ClinicalTrials.gov identifier NCT00710229]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 24]